{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T23:21:29Z","timestamp":1788304889237,"version":"build-2803163510"},"reference-count":14,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100029611","name":"Association of Schools and Colleges of Optometry","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100029611","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P01-129243"],"award-info":[{"award-number":["P01-129243"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["1R01CA226864-01A1"],"award-info":[{"award-number":["1R01CA226864-01A1"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["1R01CA251591 01A1"],"award-info":[{"award-number":["1R01CA251591 01A1"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["1R01CA273224-01"],"award-info":[{"award-number":["1R01CA273224-01"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["T32-CA009207"],"award-info":[{"award-number":["T32-CA009207"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002192","name":"LUNGevity Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002192","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006293","name":"American Society of Clinical Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006293","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jto.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.jtho.2023.09.1444","type":"journal-article","created":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T11:24:12Z","timestamp":1695468252000},"page":"153-159","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["Brief Report: Tyrosine Kinase Inhibitors for Lung Cancers That Inhibit MATE-1 Can Lead to \u201cFalse\u201d Decreases in Renal Function"],"prefix":"10.1016","volume":"19","author":[{"given":"Monica F.","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guilherme","family":"Harada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dazhi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ray","family":"DeMatteo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Falcon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clare","family":"Wilhelm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark G.","family":"Kris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Drilon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Gutgarts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtho.2023.09.1444_bib1","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1002\/cpt.445","article-title":"Transporters affecting biochemical test results: creatinine-drug interactions","volume":"100","author":"Chu","year":"2016","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jtho.2023.09.1444_bib2","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A\u00a0new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jtho.2023.09.1444_bib3","doi-asserted-by":"crossref","first-page":"c187","DOI":"10.1159\/000328911","article-title":"Trimethoprim, creatinine and creatinine-based equations","volume":"119","author":"Delanaye","year":"2011","journal-title":"Nephron Clin Pract"},{"key":"10.1016\/j.jtho.2023.09.1444_bib4","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/clpt.2010.232","article-title":"Prediction of fluoroquinolone-induced elevation in serum creatinine levels: a case of drug-endogenous substance interaction involving the inhibition of renal secretion","volume":"89","author":"Imamura","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jtho.2023.09.1444_bib5","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.clml.2015.12.001","article-title":"Imatinib increases serum creatinine by inhibiting its tubular secretion in a reversible fashion in chronic myeloid leukemia","volume":"16","author":"Vidal-Petiot","year":"2016","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.jtho.2023.09.1444_bib6","doi-asserted-by":"crossref","first-page":"9237","DOI":"10.1038\/s41598-018-27672-y","article-title":"Effect of tyrosine kinase inhibitors on renal handling of creatinine by MATE1","volume":"8","author":"Omote","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.jtho.2023.09.1444_bib7","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1158\/1535-7163.MCT-10-0731","article-title":"Interactions of tyrosine kinase inhibitors with organic cation transporters and multidrug and toxic compound extrusion proteins","volume":"10","author":"Minematsu","year":"2011","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.jtho.2023.09.1444_bib8","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1080\/00498254.2021.1875516","article-title":"Differential in\u00a0vitro interactions of the Janus kinase inhibitor ruxolitinib with human SLC drug transporters","volume":"51","author":"Bruy\u00e8re","year":"2021","journal-title":"Xenobiotica"},{"key":"10.1016\/j.jtho.2023.09.1444_bib9","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1002\/cpt.1296","article-title":"Abemaciclib inhibits renal tubular secretion without changing glomerular filtration rate","volume":"105","author":"Chappell","year":"2019","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jtho.2023.09.1444_bib10","doi-asserted-by":"crossref","first-page":"c179","DOI":"10.1159\/000339789","article-title":"KDIGO clinical practice guidelines for acute kidney injury","volume":"120","author":"Khwaja","year":"2012","journal-title":"Nephron Clin Pract"},{"key":"10.1016\/j.jtho.2023.09.1444_bib11","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1002\/jcph.1750","article-title":"Tucatinib inhibits renal transporters OCT2 and MATE without impacting renal function in healthy subjects","volume":"61","author":"Topletz-Erickson","year":"2021","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.jtho.2023.09.1444_bib12","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.kint.2021.12.010","article-title":"A\u00a0prospective cross-sectional study estimated glomerular filtration rate from creatinine and cystatin C in adults with solid tumors","volume":"101","author":"Costa E Silva","year":"2022","journal-title":"Kidney Int"},{"key":"10.1016\/j.jtho.2023.09.1444_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.cct.2021.106515","article-title":"Eligibility criteria and clinical trials: an FDA perspective","volume":"109","author":"Duggal","year":"2021","journal-title":"Contemp Clin Trials"},{"key":"10.1016\/j.jtho.2023.09.1444_bib14","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.34067\/KID.0003202022","article-title":"Advantages, limitations, and clinical considerations in using cystatin C to estimate GFR","volume":"3","author":"Chen","year":"2022","journal-title":"Kidney360"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086423022475?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086423022475?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:52:44Z","timestamp":1761562364000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086423022475"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S1556086423022475"],"URL":"https:\/\/doi.org\/10.1016\/j.jtho.2023.09.1444","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Brief Report: Tyrosine Kinase Inhibitors for Lung Cancers That Inhibit MATE-1 Can Lead to \u201cFalse\u201d Decreases in Renal Function","name":"articletitle","label":"Article Title"},{"value":"Journal of Thoracic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtho.2023.09.1444","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 International Association for the Study of Lung Cancer. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}